X4 PHARMACEUTICALS, INC Stock Split Ratio
X4 PHARMACEUTICALS, INC (XFOR) had Stock Split Ratio of 3.33% as of 2025-04-28, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-03-17
- 2025-04-28: Stockholders' Equity Note, Stock Split, Conversion Ratio 3.33%.
- 2019-03-13: Stockholders' Equity Note, Stock Split, Conversion Ratio 16.67%.
- 2017-11-03: Stockholders' Equity Note, Stock Split, Conversion Ratio 29.30%.
- 2015-08-31: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 16.67%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|---|
| 2025-04-28 | 3.33% 10-K · filed 2026-03-17 | |
| 2019-03-13 | 16.67% 10-K · filed 2020-03-12 | |
| 2017-11-03 | 29.30% 10-Q · filed 2018-11-09 | |
| 2015-08-31 | 16.67% 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |